Asensia Diabetes Care said today it renewed a diabetes management development partnership with Medtronic (NYSE:MDT), through which Ascensia will retain exclusive rights to co-develop and supply Contour Next Link and Contour Plus Link blood glucose monitors.
The Contour blood glucose meters are wirelessly compatible and designed to communicate with Medtronic’s integrated insulin pump and continuous glucose monitoring systems, Asensia said.
“To date we have launched three meter generations with Medtronic MiniMed insulin pump systems across the world and have seen tremendous success with this alliance. Medtronic is leading the path towards the artificial pancreas through their research and development. It is testament to the high quality and remarkable accuracy of our blood glucose monitoring systems that Medtronic has chosen them as part of their MiniMed insulin pump systems. We are delighted to collaborate with Medtronic on future insulin pump systems to simplify and improve the lives of people with diabetes,” CEO Michael Kloss said in a press release.
The renewal extends the partnership for 5 years, the companies said.
“Medtronic aims to transform diabetes care around the world through continuous product innovations so that people living with diabetes can enjoy greater freedom and better health. We are excited to continue our strategic alliance with Ascensia as we strive to achieve this goal,” Medtronic intensive insulin management biz prez Alejandro Galindo said in prepared remarks.
Ascensia was formed in January through the sale of Bayer‘s (ETR:BAYN) Diabetes Care biz to Panasonic (NYSE:PC).
The diabetes business operates as a stand alone company, separate from Panasonic, with a focus on developing, manufacturing and marketing blood glucose monitoring meters and strips.
The post Ascensia Diabetes reups development deal with Medtronic appeared first on MassDevice.